Abstract:Background Atherosclerosis (AS) is a multifaceted disease characterized by disruptions in lipid metabolism, vascular inflammation, and the involvement of diverse cellular constituents. Recent investigations have progressively underscored the role of microRNA (miR) dysregulation in cardiovascular diseases, notably AS. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) can effectively reduce circulating levels of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp (a)], potentially fostering a more enduring phenotype for AS plaques. However, the underlying mechanisms by which PCSK9i enhances plaque stability remain unclear. In this study, we used microarray and bioinformatics techniques to analyze the regulatory impacts on gene expression pertinent to AS, thereby unveiling potential mechanisms underlying the plaque-stabilizing attributes of PCSK9i. Methods ApoE−/− mice were randomly allocated into control, AS, PCSK9i, and Atorvastatin groups. The AS model was induced through a high-fat diet (HFD), succeeded by interventions: the PCSK9i group was subjected to subcutaneous SBC-115076 injections (8 mg/kg, twice weekly), and the Atorvastatin group received daily oral Atorvastatin (10 mg/kg) while on the HFD. Subsequent to the intervention phase, serum analysis, histological assessment using hematoxylin and eosin (H&E) and Oil Red O staining, microarray-centered miRNA analysis utilizing predictions from TargetScan and miRTarBase, and analyses using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were executed to illuminate potential pathways. Real-time fluorescence quantitative PCR (RT-qPCR) was employed to quantify the expression levels of target genes. Results In comparison to the control group, the AS group displayed a significant elevation in blood lipid levels. Both PCSK9i and Atorvastatin effectively attenuated blood lipid levels, with PCSK9i exhibiting a more pronounced lipid-lowering impact, particularly concerning TG and LDL-C levels. Over the course of AS progression, the expression levels of mmu-miR-134, mmu-miR-141-5p, mmu-miR-17-3p, mmu-miR-195-3p, mmu-miR-210, mmu-miR-33–5p, mmu-miR-410, mmu-miR-411-5p, mmu-miR-499, mmu-miR-672-5p, mmu-miR-675-3p, and mmu-miR-301b underwent dynamic fluctuations. PCSK9i significantly down-regulated the expression of mmu-miR-186-5p, mmu-miR-222, mmu-miR-375-3p, and mmu-miR-494-3p. Further enrichment analysis disclosed that mmu-miR-186-5p, mmu-miR-222, mmu-miR-375-3p, and mmu-miR-494-3p were functionally enriched for cardiovascular smooth muscle cell proliferation, migration, and regulation. RT-qPCR results manifested that, in comparison to the AS group, PCSK9i significantly upregulated the expression of Wipf2, Pdk1, and Yap1 ( p < 0.05). Conclusion Aberrant miRNA expression may play a pivotal role in AS progression in murine models of AS. The subcutaneous administration of PCSK9i exerted anti-atherosclerotic effects by targeting the miR-186-5p/Wipf2 and miR-375-3p/Pdk1/Yap1 axes, thereby promoting the transition of AS plaques into a more stable form.

Atorvastatin Attenuates P-Cresyl Sulfate-Induced Atherogenesis and Plaque Instability in Apoe Knockout Mice

p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cells

Tissue-specific Effects of Atorvastatin on 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Expression and Activity in Spontaneously Hypertensive Rats

Atorvastatin attenuates atherosclerotic plaque destabilization by inhibiting endoplasmic reticulum stress in hyperhomocysteinemic mice

Atorvastatin Decreased Low Density Lipoprotein Level and Improved Coronary Artery Lesion in Patients after Percutaneous Coronary Intervention

Atorvastatin Improves Plaque Stability In Apoe-Knockout Mice By Regulating Chemokines And Chemokine Receptors

Atorvastatin Improves Plaque Stability in Diabetic Atherosclerosis Through the RAGE Pathway.

P-Cresyl Sulfate is Associated with Carotid Arteriosclerosis in Hemodialysis Patients and Promotes Atherogenesis in Apoe−/− Mice

Atorvastatin Inhibits Inflammatory Response, Attenuates Lipid Deposition, and Improves the Stability of Vulnerable Atherosclerotic Plaques by Modulating Autophagy

Pravastatin Attenuates Atherosclerosis after Myocardial Infarction by Inhibiting Inflammatory Ly6Chigh Monocytosis in Apolipoprotein E Knockout Mice.

PCSK9i promoting the transformation of AS plaques into a stable plaque by targeting the miR-186-5p/Wipf2 and miR-375-3p/Pdk1/Yap1 in ApoE−/− mice

Effect of atorvastatin on atherosclerotic neovascularization in atherosclerotic rats

Atorvastatin inhibits homocysteine-induced endoplasmic reticulum stress through activation of AMP-activated protein kinase.

Atorvastatin Inhibits Homocysteine-Induced Dysfunction and Apoptosis in Endothelial Progenitor Cells.

Protocatechuic aldehyde increases pericyte coverage and mitigates pericyte damage to enhance the atherosclerotic plaque stability

P-Cresyl Sulfate Accelerates Left Ventricular Diastolic Dysfunction Associated With Chronic Kidney Disease

Urolithin A Promotes Atherosclerotic Plaque Stability by Limiting Inflammation and Hypercholesteremia in Apolipoprotein E–deficient Mice

Effects Of Atherogenic Diet And Atorvastatin Treatment On Gene Expression Profiles In The C57bl/6j Mouse Liver

Expression of CXC chemokine receptor 7 in atherosclerotic ApoE-defi-cient mice and therapeutic impact by atorvastatin

The Effects of Atorvastatin on Serum Myeloperoxidase and High Sensitive C-Reactive Protein Concentrations in Patients with Acute Coronary Syndrome

Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.